Delivery Order SPE2DB22D9316-SPE2DB25FYN63

Award Date 3/24/25
Potential Completion Date 4/14/25
Potential Value $11K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $52,912.40 firm fixed-price delivery order is for the provision of TYSABRI 300 MG/15 ML VIAL 15ML, a specialized pharmaceutical product. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program....
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $121,637.40 firm fixed-price delivery order is for the provision of Tysabri 300 mg/15 ml vials. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for a wide range of...
This federal contract award is a delivery order valued at $48,796.40 issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of 4563080750 - TYSABRI 300 MG/15 ML VIAL 15ML, a specialized pharmaceutical product. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the...
This federal contract award, valued at $42,579.60, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a delivery order under a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA. The delivery order is for Tysabri 300 mg/15 ml vials, a specialized pharmaceutical product. As a key supplier in the federal...
This federal contract award was issued to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $10,316.36 firm fixed-price delivery order contract was awarded by the Defense Logistics Agency (DLA) for the supply of the pharmaceutical product TYSABRI 300 MG/15 ML VIAL 15ML. The contract does not have a set-aside designation and is part of DMS Pharmaceutical Group's larger indefinite delivery contract (IDC) with the DLA under...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $10,316.36 firm fixed-price contract is for the delivery of the pharmaceutical product Tysabri 300 mg/15 ml vial to support the recurring medical supply needs of military healthcare facilities and veterans' medical centers. The award is not associated with a specific set-aside designation, allowing DMS...
The U.S. Department of Defense's Defense Logistics Agency (DLA) awarded a $41,265.44 firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of Tysabri 300 mg/15 ml vials over a period ending on May 15, 2024. This delivery order was issued under DMS Pharmaceutical Group's existing indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999,...
This federal contract award was issued by the Defense Logistics Agency's (DLA) Medical Supply Chain division to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $41,265.44 firm fixed-price delivery order is for the supply of TYSABRI 300 MG/15 ML vials to support the recurring medical needs of military health facilities. This award is part of a larger $499,999,999 indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA under the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, a firm fixed-price delivery order valued at $5,158.18, is for the supply of the biologic drug TYSABRI 300 MG/15 ML VIAL 15ML. This delivery order is part of a larger indefinite delivery contract (IDC) with DLA under the SPE2DB program, which has a ceiling value of up to $499,999,999 and...
This federal contract award, valued at $15,474.54, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the delivery of Tysabri 300 mg/15 ml vials. The contract is a firm fixed-price delivery order with no set-aside designation. It is part of DMS Pharmaceutical Group's larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which runs through December...
  • SPE2DB22D9316
    Indefinite Delivery Contract
  • SPE2DB22D9316-SPE2DB25FYN63
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $10,525.54 firm fixed-price delivery order is for TYSABRI 300 MG/15 ML VIAL 15ML, a specialized pharmaceutical product.

The award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) between DMS Pharmaceutical Group and the DLA under the SPE2DB program, which enables the DLA to issue delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. This IDC covers branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables across various product categories.

The contract does not have a set-aside designation, allowing DMS Pharmaceutical Group to leverage its woman-owned small business status to secure direct federal awards in the pharmaceutical supply chain supporting the Department of Defense.

Generated 6/29/25, 1:18 AM